The Immunological Basis for the Development of Tumor Cell- and Peptide-Based Vaccines for Treatment of Patients with Renal Cell Carcinoma

  • D. J. Schendel
  • E. Nößner
  • B. Maget
  • S. Kressenstein
  • K. Pantel
  • R. Oberneder
Conference paper
Part of the Ernst Schering Research Foundation Workshop book series (SCHERING FOUND, volume 20)


The failure of metastatic renal cell carcinoma (RCC) to respond to irradiation, chemotherapy or hormone therapy has left immunotherapy as the most hopeful form of treatment to date. Systemic cytokine therapy of RCC using recombinant interleukin-2 (rIL-2) alone or in combination with recombinant interferon-α (rIFN-α) has led to objective response rates of 20%–30% (Belldegrun et al. 1991; Rosenberg 1992). Nevertheless, few complete and long-lasting remissions have been achieved and severe toxic side effects limit their broad application. These obstacles have spurred efforts to develop alternative strategies to modulate immune responses of RCC patients. In particular, new approaches are sought for treatment of patients with minimal residual disease. In the forefront are attempts to develop genetically engineered tumor cell vaccines and peptide vaccines that will induce tumor-specific immune responses in vivo.


Renal Cell Carcinoma Major Histocompatibility Complex Minimal Residual Disease Renal Cell Carcinoma Patient Peptide Vaccine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Allison JP, Hurwitz AA, Leach DR (1995) Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opinion Immunol 7:682–686CrossRefGoogle Scholar
  2. Anonymous, (1996) Clinical protocols: cytokine/immunotherapy. Cancer Gene Ther 3:58–68Google Scholar
  3. Belldegrun A, Figlin R, Haas G, deKernion J (1991) Immunotherapy for metastic renal-cell carcinoma. World J Urol 9:157–159CrossRefGoogle Scholar
  4. Bernhard H, Karbach J, Wölfel T, et al. (1994) Cellular immune response to human renal-cell carcinomas: Definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones. Int J Cancer 59:837–842PubMedCrossRefGoogle Scholar
  5. Boon T, Cerottini JC, Van den Eynde B, Van der Bruggen P, Van Pel A (1994) Tumor antigens recognized by T lymphocytes. Ann Rev Immunol 12:337–365CrossRefGoogle Scholar
  6. Browning M, Krausa P (1996) Genetic diversity of HLA-A2: Evolutionary and functional significance. Immunol Today 17:165–170PubMedCrossRefGoogle Scholar
  7. Finn OJ (1993) Tumor-rejection antigens recognized by T lymphocytes. Curr Opin Immunol 5:701–708PubMedCrossRefGoogle Scholar
  8. Hersh EM, Akporiaye E, Harris D, et al. (1994) Phase I study of immunotherapy of malignant melanoma by direct gene transfer. Hum Gene Ther 5:1371–1384PubMedCrossRefGoogle Scholar
  9. Jaeger E, Bernhard H, Romero P et al. (1996) Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer 66:162–169PubMedCrossRefGoogle Scholar
  10. Jantzer P, Oberneder R, Maget B, Schendel DJ (1995) Recruitment of MHC-restricted cytotoxic T lymphocytes specific for renal cell carcinoma to the tumor in situ. In: Bukowski RM, Finke JH, Klein EA (eds) Biology of renal cell carcinoma. Springer, Berlin, Heidelberg, New York, pp 84–93Google Scholar
  11. Jantzer P, Schendel DJ (1997) Immunosurveillance against spontaneously arising human renal cell carcinomas: antigen-driven selection in the T cell receptor repertoire of tumor-infiltrating lymphocytes in vivo. Submitted.Google Scholar
  12. Kim TS, Cohen EP (1994) Immunization of mice with allogeneic fibroblasts genetically modified for interleukin-2-secretion and expression of melanoma-associated antigens stimulate predetermined classes of anti-melanoma effector cells. J Immunother 16:24–35CrossRefGoogle Scholar
  13. Knuth A, Wölfel T, Meyer zum Büschenfelde KH (1991) Cellular and humoral immune responses against cancer: implications for cancer vaccines. Curr Opin Immunol 3:659–664PubMedCrossRefGoogle Scholar
  14. Mandelboim O, Vadai E, Feldman M, Eisenbach L (1995) Expression of two H-2 K genes, syngeneic and allogeneic, as a strategy for potentiating immune recognition of tumor cells. Gene Therapy 2:757–765PubMedGoogle Scholar
  15. Marchand MP, Weynants P, Rankin E, et al. (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63:883–885PubMedCrossRefGoogle Scholar
  16. Nossner E, Schendel DJ (1997) Autologous and allogeneic tumor cell vaccines. In: Blankenstein T, Herrmann F (eds) Gene therapy: principles and applications. Chapman and Hall, WeinheimGoogle Scholar
  17. Oettgen HF (1991) Cytokines in clinical cancer therapy. Curr Opin Immunol 3:699–705PubMedCrossRefGoogle Scholar
  18. Pardoll DM (1993) New strategies for enhancing the immunogenicity of tumors. Curr Opin Immunol 5:719–725PubMedCrossRefGoogle Scholar
  19. Pardoll DM (1995) Paracrine cytokine adjuvants in cancer immunotherapy. Ann Rev Immunol 13:399–115CrossRefGoogle Scholar
  20. Parmiani G (1990) An explanation of the variable clinical response to inter-leukin2 and LAK cells. Immunol Today 11:113–115PubMedCrossRefGoogle Scholar
  21. Plautz GE, Yang ZY, Wu BY, et al. (1993) Immunotherapy of malignancy by in vivo gene transfer into tumors. Proc Natl Acad Sci USA 90:4645–4649PubMedCrossRefGoogle Scholar
  22. Rosenberg SA (1992) Karnofsky Memorial Lecture. The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180–199PubMedGoogle Scholar
  23. Schendel DJ, Wank R, Dupont B (1979) Standardization of the human in vitro cell-mediated lympholysis technique. Tissue Antigens 13:112–120PubMedCrossRefGoogle Scholar
  24. Schendel DJ, Gansbacher B, Oberneder R, Kriegmair M, Hofstetter A, Rieth-muller G, Segurado OG (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 151:4209–4220PubMedGoogle Scholar
  25. Schendel DJ, Gansbacher B (1993) Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: Modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous a interferon treatment. Cancer Res 53:4020–4025PubMedGoogle Scholar
  26. Schendel DJ, Oberneder R, Falk CS, Jantzer P, Kressenstein S, Maget B, Hofstetter A, Riethmiiller G, Nößner E (1997) Cellular and molecular analyses of major histocompatability complex (MHC)-restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J Mol Med (in press)Google Scholar
  27. Schwartz RH(1992) Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell 71:1065–1068PubMedCrossRefGoogle Scholar
  28. Slingluff CL, Jr., Hunt DF, Engelhard VH (1994) Direct analysis of tumor-associated peptide antigens. Curt Opin Immunol 6:733–740CrossRefGoogle Scholar
  29. Tahara H, Zeh HJ, Storkus WJ, et al. (1994) Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 54:182–189PubMedGoogle Scholar
  30. Van Pel A, Van der Bruggen P, Coulie PG, et al. (1995) Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev 145:229–250PubMedCrossRefGoogle Scholar
  31. Veelken H, Jesuiter H, Mackensen A, et al. (1994) Primary fibroblasts from human adults as target cells for ex vivo transfection and gene therapy. Hum Gene Ther 5:1203–1210PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1997

Authors and Affiliations

  • D. J. Schendel
  • E. Nößner
  • B. Maget
  • S. Kressenstein
  • K. Pantel
  • R. Oberneder

There are no affiliations available

Personalised recommendations